
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb is a strong player in the vision care industry, with a diverse portfolio of products and a positive sales and earnings momentum. Their entry into the premium contact lens market and upcoming launch of Beyond EDOF are expected to drive revenue and margin growth. The company's focus on research and innovation, along with its strong presence in the under-served dry eye market, position it well for future success. Their growth in key segments, including IOLs and pharmaceuticals, supports an optimistic outlook for the company's EBITDA margins.
Bears say
Bausch & Lomb is facing potential headwinds in its vision care and surgical segments, with the potential for underperforming sales and weakening consumer demand. While the company has a diverse portfolio of eye care products, its premium intraocular lenses have shown promising signs of growth, but any slowdown in this area could impact the company's overall margins. Additionally, the company's next-generation contact lens innovation pipeline may also face challenges and could impact growth expectations.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares